These results extend the work conducted by Schardt et al. evaluating the efficacy of mono- and bivalent HER3-targeting affibody constructs in an ovarian cancer xenograft model as monotherapies and in combination with carboplatin [27]. Here, ERBB3 is linked to ovarian carcinoma.